- Home
- DERM
as 07-26-2024 4:00pm EST
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SCOTTSDALE |
| Market Cap: | 89.1M | IPO Year: | 2021 |
| Target Price: | $8.50 | AVG Volume (30 days): | 61.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $8.11 | Next Earning Date: | 08-05-2024 |
| Revenue: | $79,998,000 | Revenue Growth: | 27.82% |
| Revenue Growth (this year): | -26.81% | Revenue Growth (next year): | 41.50% |
Stock Insider Trading Activity of Journey Medical Corporation (DERM)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROSENWALD LINDSAY A MD | DERM | Director | Mar 25 '24 | Buy | $3.04 | 10,000 | $30,400.00 | 144,245 | SEC Form 4 |
| ROSENWALD LINDSAY A MD | DERM | Director | Mar 22 '24 | Buy | $3.40 | 20,000 | $68,000.00 | 134,245 | SEC Form 4 |
| Smith Justin Adam | DERM | Director | Mar 22 '24 | Buy | $3.47 | 30,000 | $104,100.00 | 134,717 | SEC Form 4 |
| Maraoui Claude | DERM | President & CEO | Mar 22 '24 | Buy | $3.48 | 10,000 | $34,790.00 | 2,163,430 | SEC Form 4 |
| Benesch Joseph | DERM | Interim CFO | Feb 22 '24 | Sell | $3.75 | 2,450 | $9,187.50 | 60,710 | SEC Form 4 |
| Paley Jeffrey | DERM | Director | Nov 7 '23 | Sell | $3.48 | 2,245 | $7,812.60 | 114,472 | SEC Form 4 |
| Paley Jeffrey | DERM | Director | Nov 7 '23 | Sell | $3.76 | 255 | $958.80 | 114,217 | SEC Form 4 |
Latest Journey Medical Corporation News
DERM Breaking Stock News: Dive into DERM Ticker-Specific Updates for Smart Investing
ACCESSWIRE
9 days ago
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Zacks
14 days ago
4D Molecular Therapeutics (FDMT) Moves 11.1% Higher: Will This Strength Last?
GlobeNewswire
15 days ago
Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors
Simply Wall St.
2 months ago
Public companies are Journey Medical Corporation's (NASDAQ:DERM) biggest owners and were rewarded after market cap rose by US$26m last week
GlobeNewswire
2 months ago
Journey Medical Corporation to Participate in the Alliance Global Partners’ (A.G.P.) Virtual Healthcare Company Showcase
GuruFocus.com
2 months ago
Journey Medical Corp (DERM) (Q1 2024) Earnings Call Transcript Highlights: Navigating Growth ...
GlobeNewswire
2 months ago
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
GlobeNewswire
3 months ago
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Compare DERM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DERM Journey Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.